Atopic Dermatitis

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.

During his latest HCPLive interview, Karan Lal, DO, describes some of the major takeaways from his presentations at the South Beach Symposium, including information on atopic dermatitis.

The treatment, developed by Pfizer, has been approved by the FDA for adult patients with atopic dermatitis.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

In a recent analysis of 6 trials examining the use of dupilumab, the drug was found to be useful alongside concomitant TCS for patients with erythrodermic atopic dermatitis.

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

New research into atopic dermatitis treatment indicated that topical JAK inhibitors were safe and effective, although more research is needed regarding adverse effects.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).

New research connected dupilumab levels to OSD in atopic dermatitis patients, indicating a contribution to the development of the condition.

New research on updadacitinib’s use for atopic dermatitis patients suggests the drug may be effective for hand eczema.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.

This segment of Raj Chovatiya’s interview with HCPLive, a discussion was conducted regarding facts about abrocitinib for atopic dermatitis treatment.

During an HCPLive interview on his presentation at Winter Clinical, Raj Chovatiya discussed the use of abrocitinib on atopic dermatitis patients.

An overview of some of the biggest articles in the dermatology field covered this week, including new breakthroughs in research.

A recent study demonstrated that a combined treatment of topical corticosteroids and lebrikizumab led to reduced atopic dermatitis severity compared to the non-lebrikizumab group.

A new study from Denmark explored the ineffectiveness associated with dupilumab in certain regions of the body after long-term examination.